START (Stimulating Targeted Antigenic Responses To NSCLC) is a clinical research trial that will study and evaluate Stimuvax® (BLP25 liposome vaccine or L-BLP25), an investigational lung cancer vaccine being developed to treat patients with inoperable stage III non-small cell lung cancer (NSCLC).
Non-Small Cell Lung Cancer Clinical Research Trial
Researchers and doctors at approximately 250 medical facilities in 30 countries are studying an investigational lung cancer vaccine for treating non-small cell lung cancer (NSCLC). If you are 18 years of age or older and have inoperable stage III NSCLC, you may qualify for this clinical trial.
For more information about cancer vaccines, visit the About Cancer Vaccines page. To learn more about the START trial, go to the About the START Clinical Research Trial page.
To see if you or someone you know may qualify to participate in the START trial, complete the online prescreener questionnaire now.
Please complete the prescreener to answer questions that will determine if you may qualify for participation in the study. The questions help gauge your eligibility. You may answer these questions on behalf of a friend or family member. All information you enter will remain private. (Read our Patient Privacy Policy for more details.)
For additional information about this study, download the patient brochure.
